Multiple myeloma Car-Ts face a US grilling
The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.
Blenrep surprises again
After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.
GSK’s Blenrep Dreamm remains alive
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
Carvykti joins Abecma in adcom limbo
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
T-cell engagers enter new pivotal studies
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
Merck’s latest move is in bispecifics
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
